07:58 AM EDT, 08/20/2024 (MT Newswires) -- Tonix Pharmaceuticals ( TNXP ) said Tuesday its first patient was dosed in its phase 2, single-blind, placebo-controlled trial of TNX-1300 for treating acute cocaine intoxication in emergency departments.

TNX-1300 is a recombinant enzyme that degrades and metabolizes cocaine in cocaine users.

The trial will assess the safety and efficacy of a single 200 mg dose of TNX-1300 compared to placebo.

The primary endpoint is the reduction of systolic blood pressure 60 minutes after treatment

compared to placebo with standard of care. Secondary endpoints includes measurements of levels of cocaine and its metabolites in the blood.

The study will involve around 60 participants, with topline results expected in the H1 2025.

Price: 0.4805, Change: +0.04, Percent Change: +7.98